VALBIOTIS

INVESTORS

PRESENTATION

February 2021

  • 01. VALBIOTIS / Corporate

  • 02. TOTUM-63, to reduce the risk of type 2 diabetes

  • 03. TOTUM-070, to reduce hypercholesterolemia

  • 04. TOTUM-854, to reduce blood pressure

  • 05. TOTUM-448, to reduce non-alcoholic hepatic steatosis (NAFL)

  • 06. FINANCIAL INFORMATION

A R&D company, committed to scientific innovation, for preventing and combating metabolic diseases

Active substances from plants and based on science, to address unmet medical needs

  • • An innovative approach, enabled by a specific expertise of plants

  • • A high level of evidence, with clinical studies and health claims

  • • A pipeline of innovative active substances in Nutrition Healthcare, engineered in our R&D centers

  • • 4 patent families registered on 5 continents

Nutrition Healthcare: a portfolio of active substances, in clinical stages

TOTUM-63 / Prediabetes

TOTUM-070 / Hypercholesterolemia

TOTUM-854 / Arterial hypertension

TOTUM-448 / Fatty Liver

Phase II

Phase II/III

Study launch

Results

Mid-2020

S1 2022

Q4 2020

S1 2022

Q1 2021

2022

S2 2021

-

This is an excerpt of the original content. To continue reading it, access the original document here.

Attachments

  • Original document
  • Permalink

Disclaimer

Valbiotis SA published this content on 16 February 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 16 February 2021 15:42:07 UTC.